April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Topical Dexamethasone-Cyclodextrin Nanoparticle Eye Drops For Diabetic Macular Edema
Author Affiliations & Notes
  • Masaki Tanito
    Ophthalmology, Shimane Univ Faculty of Medicine, Izumo, Japan
  • Katsunori Hara
    Ophthalmology, Shimane Univ Faculty of Medicine, Izumo, Japan
  • Yasuyuki Takai
    Ophthalmology, Shimane Univ Faculty of Medicine, Izumo, Japan
  • Yotaro Matsuoka
    Ophthalmology, Shimane Univ Faculty of Medicine, Izumo, Japan
  • Akihiro Ohira
    Ophthalmology, Shimane Univ Faculty of Medicine, Izumo, Japan
  • Thorsteinn Loftsson
    Physical Pharmacy,
    University of Iceland, Reykjavik, Iceland
  • Einar Stefánsson
    Ophthalmology,
    University of Iceland, Reykjavik, Iceland
  • Footnotes
    Commercial Relationships  Masaki Tanito, None; Katsunori Hara, None; Yasuyuki Takai, None; Yotaro Matsuoka, None; Akihiro Ohira, None; Thorsteinn Loftsson, Dexamethasone-cyclodextrin nanoparticle eye drops (I, P); Einar Stefánsson, Dexamethasone-cyclodextrin nanoparticle eye drops (I, P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 585. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Masaki Tanito, Katsunori Hara, Yasuyuki Takai, Yotaro Matsuoka, Akihiro Ohira, Thorsteinn Loftsson, Einar Stefánsson; Topical Dexamethasone-Cyclodextrin Nanoparticle Eye Drops For Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2011;52(14):585.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To test the efficacy of topical 1.5% dexamethasone aqueous eye drops prepared by cyclodextrin nanoparticle technology (Dex-Cx) for diabetic macular edema (DME).

Methods: : In this pilot study, 16 eyes of 16 patients with chronic DME (9 males and 7 females; mean age 63 years) were consecutively recruited at the Shimane University Hospital. Patients received Dex-Cx eye drops 3 times or 6 times a day for 4 weeks. Visual acuity (VA), intraocular pressure (IOP), and central macular thickness measured by spectral domain optical coherent tomography were recorded at weeks 0 (baseline), 4, and 8. These parameters were compared among 3 time points by using Bonferroni-corrected paired t-tests. Percent change of central macular thickness from baseline to week 4 (%thickness change) was compared between groups separated by several parameters by un-paired t-test.

Results: : At weeks 0, 4, and 8, LogMAR VA (mean+/-SD) was 0.52+/-0.40, 0.37+/-0.38 (p=0.0086 vs baseline), and 0.44+/-0.40, respectively; central macular thickness (µm) was 512+/-173, 389+/-153 (p=0.0036 vs baseline), and 482+/-188 (p=0.0166 vs week 4), respectively; and IOP (mmHg) was 15.1+/-3.4, 17.3+/-4.6 (p=0.0051 vs baseline), and 15.5+/-4.2, respectively. At week 4, 11 of 16 eyes decreased central macular thickness more than 10 %, and 10 of 16 eyes improved LogMAR VA more than 0.1. Mean %thickness change was -21.4% (-65% to +9.8%). There was significant difference in %thickness change between vitrectomized (-54%) and un-vitrectomized (-17%) eyes (p=0.0138), while other parameters including age (-25% and -16% for ≤65y and >65y, respectively), sex (-17% and -27% for male and female, respectively), duration of disease (-23% and -20% for ≤6M and >6M, respectively), and lens status (-17% and -36% for phakia or pseudophakia, respectively), regimen of treatment (-15% and -35% for 3 times and 6 times/day, respectively) did not reach statistical significance. No subjects showed severe side effects related to topical Dex-Cx.

Conclusions: : Topical Dex-Cx eye drops decrease central macular thickness in DME and improves visual acuity. The efficacy of the eye drops is enhanced in vitrectomized eyes.

Clinical Trial: : http://www.umin.ac.jp/ctr/index.htm, UMIN000001790

Keywords: edema • drug toxicity/drug effects • diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×